Noteworthily, BCL2 family proteins play a key role in tumorigenesis and progression, and pharmacological inhibition or knockdown of BCL2 enhances the antigen-presenting capacity of dendritic cells while simultaneously optimizing tumor immunosurveillance. Here, BCL2 is linked to neoplasm.